country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-143471

Copy Link Print Information

WNY0824

(別名: PLK1/BRD4-IN-1)

WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET protein families, with IC₅₀ values of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide (HY-70002) resistant CRPC xenograft tumor models.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 2412707-81-2
分子式: C₃₁H₄₃N₉O₂
分子量:573.73

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

WNY0824 構造式

CAS 番号: 2412707-81-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[2]

PLK1

22 nM (IC₅₀)

BRD2

402.5 nM (IC₅₀)

BRD3

150.7 nM (IC₅₀)

BRD4

103.9 nM (IC₅₀)

BRDT

311.9 nM (IC₅₀)

Polo-like Kinase (PLK) アイソフォーム固有の製品をすべて表示 :

Epigenetic Reader Domain アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	2.82 μM Compound: 9b	Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32088495]
CWR22R	IC₅₀	0.58 μM Compound: WNY0824	Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability measured after 4 days by MTT assay Antiproliferative activity against AR-positive human 22Rv1 cells assessed as reduction in cell viability measured after 4 days by MTT assay	[PMID: 34700270]
DU-145	IC₅₀	1.465 μM Compound: WNY0824	Antiproliferative activity against AR-negative human castration resistant DU-145 cells assessed as reduction in cell viability measured after 4 days by MTT assay Antiproliferative activity against AR-negative human castration resistant DU-145 cells assessed as reduction in cell viability measured after 4 days by MTT assay	[PMID: 34700270]
HT-29	IC₅₀	2.51 μM Compound: 9b	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32088495]
LNCaP	IC₅₀	0.14 μM Compound: 9b	Cytotoxicity against human LNCaP cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human LNCaP cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32088495]
LNCaP	IC₅₀	1.451 μM Compound: WNY0824	Antiproliferative activity against AR-positive harmone sensitive human LNCaP cells assessed as reduction in cell viability measured after 4 days by MTT assay Antiproliferative activity against AR-positive harmone sensitive human LNCaP cells assessed as reduction in cell viability measured after 4 days by MTT assay	[PMID: 34700270]
MV4-11	IC₅₀	0.13 μM Compound: 9b	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32088495]
MV4-11	IC₅₀	0.13 μM Compound: WNY0824	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability measured after 4 days by MTT assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability measured after 4 days by MTT assay	[PMID: 34700270]
PC-3	IC₅₀	1.403 μM Compound: WNY0824	Antiproliferative activity against AR-negative human castration resistant PC-3 cells assessed as reduction in cell viability measured after 4 days by MTT assay Antiproliferative activity against AR-negative human castration resistant PC-3 cells assessed as reduction in cell viability measured after 4 days by MTT assay	[PMID: 34700270]
SK-OV-3	IC₅₀	1.1 μM Compound: 9b	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32088495]
VCaP	IC₅₀	0.628 μM Compound: WNY0824	Antiproliferative activity against AR-positive human VCaP cells assessed as reduction in cell viability measured after 4 days by MTT assay Antiproliferative activity against AR-positive human VCaP cells assessed as reduction in cell viability measured after 4 days by MTT assay	[PMID: 34700270]

体外実験

Cell Viability Assay^[1]

Cell Line:

MV4-11, LnCap, HT-29, A375, SKOV-3
Concentration:

Cells were maintained in RPMI 1640 or DMEM medium supplemented with 10% FBS (v/v) in 5% CO₂, except for MV4-11 cells, which were cultured in IMDM medium.
Incubation Time:

72 h
Result:

Showed broad-spectrum antiproliferative activities with IC₅₀ values of 0.13, 0.14, 1.10, 2.82 and 2.51 µM against MV4-11, LnCap, SKOV-3, A375 and HT29 cells, respectively.

Cell Cycle Analysis^[1]

Cell Line:

MV4-11
Concentration:

0.1, 0.3, 1, 3, 9 µM
Incubation Time:

24 h
Result:

Induced obvious G2/M arrest in a concentration-dependent manner

Apoptosis Analysis^[1]

Cell Line:

MV4-11
Concentration:

0.1, 0.3, 1, 3, 9 µM
Incubation Time:

48 h
Result:

Significantly increased the number of Annexin V/PI-positive MV4-11 cells in a concentration-dependent manner.

RT-PCR^[1]

Cell Line:

MV4-11
Concentration:

0.1, 0.3, 1, 3, 9 µM
Incubation Time:

24 h
Result:

Reduced the transcription of c-MYC and MYCN as well as BCL-2, in a concentration-dependent manner.

Western Blot Analysis^[1]

Cell Line:

MV4-11
Concentration:

0.1, 0.3, 1, 3, 9 µM
Incubation Time:

48 h
Result:

Decreased the expression of c-Myc and Bcl-2 in a concentration dependent-manner and upregulated cleaved caspase-3 and cleaved PARP.

体内実験

Animal Model:

Five weeks old male NOD-SCID mice^[1].
Dosage:

60 mg/kg/d
Administration:

Oral gavage, 18 days; tumor xenograft models were established by subcutaneously injecting 100 µL of 1×10⁸ cell/mL MV4-11 cell suspension into NOD-SCID mice.
Result:

Resulted in a significant decrease in average tumor size, with 66% tumor growth inhibition, and didn’t obviously affect the body weight of mice.

化学情報

CAS 番号 2412707-81-2
分子量 573.73
分子式 C₃₁H₄₃N₉O₂
SMILES

O=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(CC4CCCCC4)[C@@H]5CC)=NC=C3N6C5=NN=C6C)C(OC)=C2
別名

PLK1/BRD4-IN-1
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (269 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ning-Yu Wang, et al. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. Eur J Med Chem. 2020 Apr 1;191:112152. [Content Brief]

[2]. Ying Xu, et al. "Novel dual BET and PLK1 inhibitor WNY0824 exerts potent antitumor effects in CRPC by inhibiting transcription factor function and inducing mitotic abnormality." Molecular Cancer Therapeutics 19.6 (2020): 1221-1231. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

お問い合わせ在庫あり

Amount: USD 0.00

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

WNY0824

Polo-like Kinase (PLK) アイソフォーム固有の製品をすべて表示

Epigenetic Reader Domain アイソフォーム固有の製品をすべて表示

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

WNY0824 関連分類

HY-143471 関連分類